Cargando…
Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody
Metelimumab (CAT192) is a human IgG4 monoclonal antibody developed as a TGFβ1-specific antagonist. It was tested in clinical trials for the treatment of scleroderma but later terminated due to lack of efficacy. Subsequent characterization of CAT192 indicated that its TGFβ1 binding affinity was reduc...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916551/ https://www.ncbi.nlm.nih.gov/pubmed/29333938 http://dx.doi.org/10.1080/19420862.2018.1426421 |